Efficacy and Safety of Novel Treatment Options for Adults With COVID-19 Pneumonia
Status:
Not yet recruiting
Trial end date:
2021-06-15
Target enrollment:
Participant gender:
Summary
CCAP is an investigator-initiated multicentre, randomized, double blinded,
placebo-controlled, multi-stage trial, which aims to assess the safety and efficacy of novel
treatment option of moderate-severe COVID-19.
Participants will be randomized 1:1:1:1:1:1 to parallel treatment arms: Convalescent plasma,
sarilumab, hydroxychloroquine, baricitinib, intravenous and subcutaneous placebo, or oral
placebo.
Primary outcome is a composite endpoint of all-cause mortality or need of invasive mechanical
ventilation up to 28 days.